Login to Your Account



Financings Roundup

$33.9M Series B to Fund Omthera's Omega-3 Product

By Catherine Shaffer


Tuesday, March 15, 2011
Omthera Pharmaceuticals Inc., of Bedminster, N.J., raised $33.9 million in Series B funding and initiated Phase III trials for Epanova, its candidate for high triglycerides. The capital raised will support development of Epanova, which could take a bite out of the $2 billion worldwide market for prescription omega-3 fatty acid.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription